Thu, April 1, 2021

Geoffrey Porges Maintained (TBPH) at Buy with Decreased Target to $40 on, Apr 1st, 2021

Geoffrey Porges of SVB Leerink, Maintained "Theravance Biopharma, Inc." (TBPH) at Buy with Decreased Target from $41 to $40 on, Apr 1st, 2021.

Geoffrey has made no other calls on TBPH in the last 4 months.



There is 1 other peer that has a rating on TBPH. Out of the 1 peers that are also analyzing TBPH, 0 agree with Geoffrey's Rating of Hold.



This is the rating of the analyst that currently disagrees with Geoffrey


  • Vikram Purohit of "Morgan Stanley" Maintained at Buy with Decreased Target to $30 on, Monday, March 1st, 2021